Premera Blue Cross · Identified Jun 16, 2026Medium impact
Medical Policy and Coding Updates - July 2024
Effective July 1, 2024, Premera HMO medical necessity criteria were added or updated for several drugs, including Repatha (evolocumab), Praluent (alirocumab), Leqvio (inclisiran), Nexletol and Nexlizet, and Evkeeza (evinacumab-dgnb) for hypercholesterolemia, and the reauthorization requirement for continued use of a maximum tolerated statin was removed for Evkeeza, Juxtapid, Leqvio, Nexletol, Nexlizet, Praluent and Repatha. Effective October 20, 2024, Carelon Medical Benefits Management clinical appropriateness guidelines for radiology, cardiology, genetic testing, radiation oncology and sleep were updated, including added indications for MRI and amyloid beta PET imaging in Alzheimer disease for patients considering or receiving lecanemab. Effective October 8, 2024, surgical treatment of femoral acetabular impingement is considered medically necessary when criteria are met.